Andreas Saltos

2.6k total citations · 1 hit paper
43 papers, 671 citations indexed

About

Andreas Saltos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andreas Saltos has authored 43 papers receiving a total of 671 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Andreas Saltos's work include Lung Cancer Treatments and Mutations (27 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Research Studies (10 papers). Andreas Saltos is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Research Studies (10 papers). Andreas Saltos collaborates with scholars based in United States, Spain and Japan. Andreas Saltos's co-authors include Michael Shafique, Alberto Chiappori, Jhanelle E. Gray, Scott Antonia, Daniel C. Smith, Richard Lichenstein, Jose M. Pacheco, Enriqueta Felip, David Planchard and Pasi A. Jänne and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Andreas Saltos

41 papers receiving 660 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

2024 76 citations Egbert F. Smit, Enriqueta Felip et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andreas Saltos United States	11	415	263	191	99	87	43	671
Lauren M. Lepone United States	15	610 1.5×	150 0.6×	144 0.8×	92 0.9×	56 0.6×	25	869
Mayur D. Mody United States	8	208 0.5×	162 0.6×	214 1.1×	55 0.6×	120 1.4×	13	628
Anne Fedoroff United States	6	163 0.4×	137 0.5×	177 0.9×	40 0.4×	112 1.3×	8	553
Carole Ramirez France	9	217 0.5×	77 0.3×	272 1.4×	38 0.4×	75 0.9×	23	704
Ruolan Xia China	9	285 0.7×	86 0.3×	176 0.9×	41 0.4×	76 0.9×	14	631
Sebastian Klein Germany	13	187 0.5×	122 0.5×	122 0.6×	39 0.4×	69 0.8×	31	458
Jean‐Philippe Foy France	15	140 0.3×	86 0.3×	156 0.8×	40 0.4×	102 1.2×	42	552
Jennifer Moy United States	10	407 1.0×	92 0.3×	130 0.7×	43 0.4×	71 0.8×	13	652
Suresh Mohan United States	12	123 0.3×	74 0.3×	235 1.2×	42 0.4×	72 0.8×	39	616
James Clune United States	11	240 0.6×	38 0.1×	140 0.7×	74 0.7×	48 0.6×	56	550

Countries citing papers authored by Andreas Saltos

Since Specialization

Citations

This map shows the geographic impact of Andreas Saltos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Saltos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Saltos more than expected).

Fields of papers citing papers by Andreas Saltos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Saltos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Saltos. The network helps show where Andreas Saltos may publish in the future.

Co-authorship network of co-authors of Andreas Saltos

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Saltos. A scholar is included among the top collaborators of Andreas Saltos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Saltos. Andreas Saltos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dragnev, Konstantin H., Mary W. Redman, Karen L. Reckamp, et al.. (2025). PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 43(17_suppl).

Punekar, Salman R., Jia Luo, S-H.I. Ou, et al.. (2025). 6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 20(3). S10–S11. 1 indexed citations

Alontaga, Aileen Y., Pedro Cano, John Puskas, et al.. (2024). Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care. Journal of Molecular Diagnostics. 26(8). 685–699. 2 indexed citations

Smit, Egbert F., Enriqueta Felip, Dipesh Uprety, et al.. (2024). Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. The Lancet Oncology. 25(4). 439–454. 76 indexed citations breakdown →

Saltos, Andreas, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.. Journal of Clinical Oncology. 41(16_suppl). 9125–9125. 2 indexed citations

Thapa, Ram, Michael Shafique, Andreas Saltos, et al.. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease. 15(11). 6115–6125. 4 indexed citations

Chen, Dung‐Tsa, Andreas Saltos, Trevor Rose, et al.. (2023). Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers. 15(9). 2521–2521. 2 indexed citations

Yu, Xiaoqing, Mengyu Xie, Joseph Johnson, et al.. (2023). Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunology Research. 11(4). 466–485. 9 indexed citations

Saltos, Andreas, Ben Creelan, Tawee Tanvetyanon, et al.. (2023). A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 183. 107313–107313. 3 indexed citations

10.

Le, Xiuning, Elaine Shum, Christina S. Baik, et al.. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology. 34. S1313–S1314. 8 indexed citations

11.

Puri, Sonam, Tawee Tanvetyanon, Ben Creelan, et al.. (2023). The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.. Journal of Clinical Oncology. 41(16_suppl). 9102–9102. 1 indexed citations

12.

Dudek, Arkadiusz Z., Katherine A. Scilla, Hirva Mamdani, et al.. (2023). Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299. JTO Clinical and Research Reports. 4(12). 100584–100584. 1 indexed citations

13.

Chen, Dung‐Tsa, Wenyaw Chan, Zachary Thompson, et al.. (2021). Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS ONE. 16(7). e0252041–e0252041. 4 indexed citations

14.

Saltos, Andreas, Michael Shafique, & Alberto Chiappori. (2020). Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). Frontiers in Oncology. 10. 1074–1074. 103 indexed citations

15.

Puri, Sonam, Andreas Saltos, Bradford A. Perez, Xiuning Le, & Jhanelle E. Gray. (2020). Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Current Oncology Reports. 22(4). 31–31. 18 indexed citations

16.

Saltos, Andreas & Scott Antonia. (2020). Breaking the Impasse. Clinics in Chest Medicine. 41(2). 269–280. 7 indexed citations

17.

Gray, Jhanelle E., Andreas Saltos, Tawee Tanvetyanon, et al.. (2019). Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(22). 6623–6632. 104 indexed citations

18.

Niyongere, Sandrine, Andreas Saltos, & Jhanelle E. Gray. (2018). Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. Journal of Thoracic Disease. 10(S3). S433–S450. 15 indexed citations

19.

Dagogo‐Jack, Ibiayi, Andreas Saltos, Alice T. Shaw, & Jhanelle E. Gray. (2017). Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. American Society of Clinical Oncology Educational Book. 37(37). 619–629. 6 indexed citations

20.

Smith, Daniel C., et al.. (2013). Ambulatory cell phone injuries in the United States. Journal of Safety Research. 47. 19–23. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact